Close Menu

NEW YORK (GenomeWeb) – Roche announced this week that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta for $27 per share. The tender offer is being made pursuant to a merger agreement entered into by Ignyta and Roche on Dec. 21, and will expire on Feb. 7. Following successful completion of the tender offer, any shares not acquired will be acquired in a second step merger at the same price of $27 per share. The closing of the transaction is expected to take place in the first half of 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.